Nipent Alternatives Compared
Nipent (pentostatin) | Cladribine | Intron A (interferon alfa-2b) |
|
---|
Nipent (pentostatin) | Cladribine | Intron A (interferon alfa-2b) |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Hairy Cell Leukemia. Nipent may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Hairy Cell Leukemia, Multiple Sclerosis. Cladribine may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Angioblastoma, Condylomata Acuminata, Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Follicular Lymphoma, Hairy Cell Leukemia, Hepatitis B, Hepatitis C, Immune... View more |
Related suggestions Hairy Cell Leukemia
|
|||||||||||||||
More about Nipent (pentostatin) | More about Cladribine | More about Intron A (interferon alfa-2b) | ||||||||||||||||
Ratings & Reviews | ||||||||||||||||||
Be the first to share your experience with this drug. |
Cladribine has an average rating of 8.0 out of 10 from a total of 10 ratings on Drugs.com. 70% of reviewers reported a positive effect, while 20% reported a negative effect. |
Intron A has an average rating of 3.3 out of 10 from a total of 4 ratings on Drugs.com. 25% of reviewers reported a positive effect, while 75% reported a negative effect. |
||||||||||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
View all Nipent side effects |
View all Cladribine side effects |
View all Intron A side effects |
||||||||||||||||
Drug Class | ||||||||||||||||||
Generic Availability | ||||||||||||||||||
Lower cost generic |
N/A |
|||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
View all Nipent prices |
View all Cladribine prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||||||||||
Dosage Forms | ||||||||||||||||||
|
|
|
||||||||||||||||
Brand Names | ||||||||||||||||||
N/A |
Cladribine Novaplus, Mavenclad |
N/A |
||||||||||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
15 hours |
6.7 hours |
3 hours |
||||||||||||||||
CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | ||||||||||||||||||
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | ||||||||||||||||||
A total of 246 drugs are known to interact with Nipent:
|
A total of 505 drugs are known to interact with Cladribine:
|
A total of 263 drugs are known to interact with Intron A:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
Disease Interactions | ||||||||||||||||||
First Approval Date | ||||||||||||||||||
October 11, 1991 |
March 29, 2019 |
N/A |
||||||||||||||||
WADA Class View classifications | ||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||
More Information | ||||||||||||||||||
Patient Resources | ||||||||||||||||||
Professional Resources | ||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.